LFMD LifeMD, Inc.companySEC Filings & Insider Trading Activity 2026
Latest LifeMD, Inc. (LFMD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 10, 2026, a 10-Q quarterly report filed on November 17, 2025, an 8-K current report filed on March 18, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for LifeMD, Inc. (LFMD) (SEC CIK 948320), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: vertically integrated virtual healthcare and pharmacy platform serving 328,000 active subscribers primarily via subscription telehealth
- • New pharmacy facility opened Nov 2024 with 22,500 sq ft, 5,000 daily prescription capacity; added advanced non-sterile compounding in Sept 2025
Risk Factors
- • Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage
- • Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place
Management Discussion & Analysis
- • Revenue $210M, up 5% YoY from $200M in 2024
- • Operating margin 18.2% vs 16.9% in prior year
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No new risk factors added this quarter; risks same as 2024 10-K
- • Most material risk carried forward: significant regulatory scrutiny from SEC and state health authorities
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Item 5.02 covers officer/director changes with implications for company leadership
- • This filing lacks specific details on personnel changes or compensation terms
Item 8.01: Other Events
- • CFO Marc Benathen resigned; Atul Kavthekar appointed new CFO, signaling potential strategic or financial leadership shift
- • Jessica Friedeman promoted to Chief Business Officer, likely to influence business development and corporate growth strategies
Item 2.02: Results of Operations and Financial Condition
- • Q4 2025 and full-year 2025 financial results announced March 9, 2026
- • 2026 earnings guidance also disclosed — key forward-looking signal for investors
Item 7.01: Regulation FD Disclosure
- • Investor presentation filed as Exhibit 99.2, in use starting March 9, 2026 — check exhibit for strategic/financial details
- • Presentation covers projected industry growth rates, company growth rates, and cash flow positioning per forward-looking statements disclosure
Annual Reports Archive10-K
AI-powered analysis of LifeMD, Inc. (LFMD) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of LifeMD, Inc. (LFMD) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of LifeMD, Inc. (LFMD) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $119.0M | $152.5M | $212.5M | $194.1M |
| Gross Profit | $100.4M | $133.6M | $188.4M | $166.3M |
| Operating Income | — | -$14.5M | -$16.1M | -$7.7M |
| Net Income | — | -$20.6M | -$18.9M | $14.4M |
| Gross Margin | 84.3% | 87.6% | 88.7% | 85.7% |
| Op. Margin | — | -9.5% | -7.6% | -4.0% |
| Net Margin | — | -13.5% | -8.9% | 7.4% |
| Balance Sheet | ||||
| Total Assets | — | $58.5M | $72.5M | $70.4M |
| Equity | — | $3.5M | -$5.5M | $23.2M |
| ROE | — | -587.6% | 344.2% | 62.0% |
Source: XBRL financial data from LifeMD, Inc. (LFMD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 18, 2026 | — | Analysis | — |
10-K | Mar 10, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Jan 6, 2026 | — | — | |
10-Q | Nov 17, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Mar 11, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Mar 11, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 12, 2023 | Mar 31, 2023 | — | |
10-K | Mar 22, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 13, 2022 | Mar 31, 2022 | — | |
10-K | Mar 7, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 13, 2021 | Jun 30, 2021 | — | |
10-Q | May 14, 2021 | Mar 31, 2021 | — | |
10-K | Mar 30, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 16, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest LFMD SEC filings in 2026?
LifeMD, Inc. (LFMD) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 17, 2025, an 8-K current report on March 18, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did LFMD file its most recent 10-K annual report?
LifeMD, Inc. (LFMD) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view LFMD 10-Q quarterly reports?
LifeMD, Inc. (LFMD)'s most recent 10-Q quarterly report was filed on November 17, 2025. SignalX displays every LFMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has LFMD filed recently?
LifeMD, Inc. (LFMD)'s most recent 8-K was filed on March 18, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find LFMD insider trading activity (Form 4)?
SignalX aggregates every LFMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does LFMD file with the SEC?
LifeMD, Inc. (LFMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LFMD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LifeMD, Inc. (LFMD).
What is LFMD's SEC CIK number?
LifeMD, Inc. (LFMD)'s SEC CIK (Central Index Key) number is 948320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 948320 to look up all LFMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find LFMD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from LifeMD, Inc. (LFMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of LifeMD, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 56+ filings.